ANI Pharmaceuticals Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ANI Pharma (ANIP) Misses Q3 EPS by 20c, Revenues Miss; Offers FY19 EPS/Revenue Guidance Below Consensus
November 6, 2019 8:32 AM ESTANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.23, $0.20 worse than the analyst estimate of $1.43. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.97 million.
For the third quarter 2019:
Net revenues of $51.3 million, an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32Adjusted non-GAAP EBITDA of $19.8 million and... More